ABOUT US

Making a Difference

Cervilenz Inc. is dedicated to helping reduce the rates of preterm birth and infant mortality. The company was founded in 2008 by Dean Koch, Michael Ross, MD, MPH, and Rosalyn Baxter-Jones, MD. The company is headquartered in Chagrin Falls, a suburb of Cleveland, Ohio. The device is manufactured in Cincinnati, Ohio.

Kevin Bramer is President and CEO and a member of the Board of Directors; he joined the company in October 2014. Kevin also currently serves as Chairman of NX Prenatal (molecular diagnostics preterm birth assay), having raised nearly $2M in 2013 to launch the company from its predecessor, NX PharmaGen. Kevin served as President and CEO of Prescript Link, Inc. (medical information technology) in 2014 and as President and CEO of MedVenture (minimally invasive medical devices) from 2001 through 2013, with other roles there dating back to 1998. At MedVenture, Kevin grew revenues from $5M in 2001 to over $60M in 2013, and sold the company to Ampersand Ventures in 2008 and to Freudenberg NOK in 2012.

Dean Koch founded the company in 2008 and is a member of the executive team, bringing over 25 years of experience with novel medical devices, diagnostics, and therapeutics. At Adeza Biomedical, Dean led the commercialization of a laboratory test for preterm birth prediction and the market planning for a new drug for preterm birth prevention. As Vice President of Sales, Dean built the sales organization to over 100 sales representatives and managers. Dean also served as Vice President of Marketing from 2006 until the sale of Adeza to Cytyc, Inc. in 2007 for $450 million. Cytyc has since merged with Hologic, Inc.

Melanie Sweeney is Vice President; she joined the company in 2009. Melanie has over 20 years of experience in the world of prematurity. Melanie founded and managed Partners in Intensive Care, a community-based nonprofit organization in Washington DC, from 1994 to 1998, and consulted to the Institute for Family-Centered Care. Volunteering for the March of Dimes since 1995, Melanie helped develop Family Teams for the March for Babies and the NICU Family Support program. Melanie worked for the March of Dimes National Office as the Director of Mission Volunteer Initiatives from 2005 to 2009. Melanie also brings experience as a human factors engineer to the design and use of medical devices.

Michael Ross, MD, MPH is a founder of the company, a member of the Board of Directors, and Medical Director. Dr. Ross is a board certified Maternal-Fetal Medicine physician and Distinguished Professor of Obstetrics and Gynecology and Public Health at the Geffen School of Medicine and the Fielding School of Public Health at UCLA. He has over 300 peer reviewed publications, 600 published abstracts, and edited or wrote five books and numerous book chapters. Dr. Ross is Editor of the Journal of Developmental Origins of Health and Disease, and a member of the Editorial Board of the American Journal of Physiology and Reproductive Sciences. He is a recognized expert in fetal physiology and clinical obstetrics. His research has been funded by the National Institutes of Health, March of Dimes, and American Heart Association.

Rosalyn Baxter-Jones, MD is a founder of the company. Dr. Baxter-Jones is a board certified Obstetrician/Gynecologist with 25 years of experience practicing in a variety of settings, currently as a hospitalist with Goodman & Partridge OB/GYN in Arizona. Dr. Baxter-Jones invented the CerviLenz device, inspired by the need for a simple, immediate method to measure cervical length and assess preterm birth risk for her patients during a routine prenatal visit.

Making it Happen

Cervilenz Inc. is grateful for the funding provided by these and other valued investors.


Stay in touch on Facebook

Get announcements and research updates, learn more about how obstetricians and midwives are using the CerviLenz device, and interact with us and your colleagues. Plus, get all the latest news on preterm birth risk assessment, cervical length measurement, high risk patient management, therapies such as progesterone, and more!

Connect with us on Facebook